BioSpace News Archive

Received a Complete Response Letter (“CRL”) from the United States Food and Drug Administration (“FDA”) regarding the New Drug Application (“NDA”) for TLANDO™, the Company’s oral testosterone product candidate for testosterone replacement therapy (“TRT”) in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism.

Presentation scheduled for 9:10 a.m. ET on August 15, 2018

Aerpio Pharmaceuticals, Inc. announced that its second quarter 2018 financial results will be released before the market opens on Tuesday, August 14, 2018.

Accelerate Diagnostics, Inc. announced that it received an Innovative Technology contract from Vizient, Inc., the largest member-driven health care performance improvement company in the United States.

The Genomics 2.0 Summit is in Park City, Utah; Thursday, August 9, 2018 at 11:30 am.

Onconova Therapeutics, Inc. announced that the Company will release its second quarter 2018 financial results on August 14, 2018 before the market opens.

EVIO Inc. announced that its Massachusetts lab has submitted its license application to the state’s Cannabis Control Commission and is seeking approval to be licensed as an independent testing laboratory under the Commission’s recently adopted adult use regulations.

2019 National Preferred Formulary includes low list price medications in high-cost categories

Darling Ingredients Inc. will hold a conference call and webcast on Thursday, August 9, 2018 to discuss the Company’s second quarter 2018 financial results.

Key Addition to Infinity’s Clinical Development Team Brings Recent Experience Leading First-in-Class, Targeted Oncology Programs Through FDA Approvals